Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00817258|
Recruitment Status : Unknown
Verified January 2009 by Fudan University.
Recruitment status was: Recruiting
First Posted : January 6, 2009
Last Update Posted : January 6, 2009
The primary objective of this study is to determine the overall survival in patients with stage II (T1-2N1M0) NPC treated with concurrent chemotherapy and radiotherapy.
Secondary objectives of the study are to evaluate the disease free survival, and distant metastases free survival of patients with stage II NPC treated with this regimen
|Condition or disease||Intervention/treatment||Phase|
|Nasopharyngeal Carcinoma||Drug: cisplatin Radiation: 3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||37 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase Ⅱ Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma|
|Study Start Date :||January 2007|
|Estimated Primary Completion Date :||June 2009|
|Estimated Study Completion Date :||December 2009|
All patients will receive radical radiotherapy with 3D-CRT or IMRT, and cisplatin (40mg/m2) weekly during external radiotherapy.
Cisplatin 40mg/m2,weeklyRadiation: 3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)
3D-CRT or IMRT
- overall survival [ Time Frame: 3 and 5 years ]
- disease-free survival, and distant metastases free survival [ Time Frame: 3 and 5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00817258
|Contact: Lin Kong, MD||8621-64175590 ext firstname.lastname@example.org|
|Department of Radiation Oncology, Cancer Hospital, Fudan University||Recruiting|
|Shanghai, China, 200032|
|Contact: Jing Yuan 8621-64175590 ext 6511 email@example.com|
|Principal Investigator:||Lin Kong, MD||Department of Radiation Oncology, Cancer Hospital, Fudan University|
|Principal Investigator:||Chaosu Hu, MD||Department of Radiation Oncology, Cancer Hospital, Fudan University|